Estimation and validation of acenocoumarol dosing algorithms in Bulgarian patients with cardiovascular diseases

Personalized Medicine
Reni TzveovaRadka Kaneva

Abstract

Aim & Methods: A total of 169 Bulgarian patients were genotyped for CYP2C9*2,*3, VKORC1-1639G>A and VKORC11173C>T. The effect of genetic and nongenetic factors on acenocoumarol dose variability was tested in a derivation cohort of patients and the obtained algorithm was validated in a test cohort. It was found that VKORC-1639G>A (25.5%), CYP2C9*2 (7.8%), CYP2C9*3 (6.1%), age (13.6%) and diagnosis (6.0%) significantly affected acenocoumarol dose variability in the derivation cohort. These factors with additional factors, such as sex (0.1%, p = 0.76), weight (2.6%, p = 0.14) and amiodarone use (3.0%, p = 0.059) accounted for 46.5% and 23.0% of the dose variability for genetic and clinical models, respectively. Based on the results of this investigation, validated clinical and pharmacogenetic algorithms for the prediction of a stable anticoagulant dose were developed, specifically designed for the Bulgarian population.

References

Aug 1, 1992·Journal of Clinical Pathology·A H JamesS G Thompson
Aug 15, 2001·Clinical Pharmacology and Therapeutics·R LoebsteinD Ezra
Mar 7, 2003·Clinical Pharmacology and Therapeutics·Harumi TakahashiHirotoshi Echizen
Jun 4, 2004·Thrombosis and Haemostasis·Hylton V JoffeSamuel Z Goldhaber
Jan 22, 2005·Fundamental & Clinical Pharmacology·Rosemary JoseKrishnamoorthy Rajagopal
Jun 3, 2005·The New England Journal of Medicine·Mark J RiederAllan E Rettie
Apr 26, 2007·Clinical Medicine & Research·Michael D CaldwellJames K Burmester
Sep 4, 2007·Journal of Thrombosis and Haemostasis : JTH·M J RiederA E Rettie
Nov 21, 2008·Pharmacogenomics·Christos N MarkatosAnthi Travlou
Mar 10, 2009·Blood·Virginia Pérez-AndreuRocio González-Conejero
Jun 29, 2010·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Mirjana K KovacDragica P Radojkovic
Aug 3, 2010·Annals of Medicine·Diana Hernández-RomeroRocío González-Conejero
Apr 22, 2011·Journal of Clinical Pharmacy and Therapeutics·L K TehM Z Salleh
Jun 4, 2011·Journal of Thrombosis and Thrombolysis·Mirjana K KovacDragica P Radojkovic
Aug 3, 2012·Journal of Human Genetics·Anil PathareRajagopal Krishnamoorthy
Oct 16, 2012·Basic & Clinical Pharmacology & Toxicology·Mahmut ÖzerEce Genç
Nov 20, 2012·Blood Cells, Molecules & Diseases·Anca Dana BuzoianuSorin Crişan
Dec 1, 2012·Thrombosis and Haemostasis·Juan J Cerezo-ManchadoVanessa Roldán
Mar 12, 2013·Thrombosis Research·Dhakchinamoorthi Krishna KumarChandrasekaran Adithan
Jun 19, 2013·European Journal of Clinical Pharmacology·Tudor Radu PopAnca Dana Buzoianu

❮ Previous
Next ❯

Citations

Feb 27, 2018·European Journal of Clinical Pharmacology·Marwa AjmiAli Bouslama

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay
genotyping

Software Mentioned

Statistical Package for Social Sciences for ( SPSS

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

© 2022 Meta ULC. All rights reserved